Vabysmo 6mg ((0.05) mL) is a prescription intravitreal injection containing faricimab-svoa, designed for adults to treat wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It is the first bispecific antibody for the eye, targeting both VEGF and Ang-2 pathways to reduce vessel leakage, swelling, and improve vision. Key Details for Vabysmo 6mg: Mechanism: It works by blocking vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), which cause leakage and abnormal blood vessel growth.Dosage: The recommended dose is 6 mg ((0.05) mL) administered by a qualified physician via intravitreal injection, typically monthly for the first 4 doses, followed by extended intervals of up to every 4 months (16 weeks).Administration: It is injected directly into the eye (intravitreal) by an eye specialist.Side Effects: Common side effects include conjunctival hemorrhage (blood on the white of the eye), cataracts, eye floaters, eye pain, and increased eye pressure.